Bone marrow-derived mononuclear cells for the treatment of cerebral palsy

The aim of two clinical trials is to test the safety and efficacy of autologous bone marrow-derived mononuclear cells (MNCs) in treating either adult (>15-years-old) or juvenile (<15-years-old) cerebral palsy patients.